This company has developed proprietary software and IP that affords pharmaceutical companies the ability to track, in near real-time, information on their drugs, both sales transaction data and inventory movements. This is a game changer for an industry that currently makes their business decisions based on reports that come from CRO’s provided to them typically only on a quarterly basis.
Since launching with Proof of Concept in 2018, this company has been able to establish meaning relationships with pharmaceutical distributors in 4 countries. Today, they have exclusive rights to data collection for over 80% of the market in each of the countries they are in.
The company maintains an exhaustive list of all pharmaceutical products sold in those 4 countries. To date, they track over 10,000 unique entries, and have amassed data on over 350 million sales transactions. The company is the sole owner of the data it collects, and they act as a trusted fiduciary to their clients, providing them with a software platform that is intuitive to use, all built and maintained in accordance with industry best practices, held in a highly secure ecosystem with strict management protocols.
INVESTMENT HIGHLIGHTS:
• The company maintains an outstanding reputation for being a trusted fiduciary to the pharmaceutical industry.
• Solid team of highly skilled people in place looking forward to continuing the company’s growth.
• Industry changing software and IP in a growing multi-billion-dollar industry.
• The current Serviceable Obtainable Market in the 4 countries they operate in is currently estimated to be $30MM. The Global Market is expected to grow at an annualized rate of 7.7% to $26.5 Billion by 2027.
Real Estate Available: No
Real Estate Included: No
Detailed Information:
Lender Prequalified: No
SBA Prequalified: No
Is Going Concern: Yes
